Vol 20, No 1 (2015)


Systematic review of the YB-1 protein prognostic value in breast cancer patients: overall and progression free survival

Guens G.P., Fedyaeva V.K., Rebrova O.Y.


Breast cancer (BC) is the most common cancer among women worldwide. The role of the multi-Y-box binding protein 1 (YB-1) as a prognostic marker in relation to BC aggressiveness and resistance of tumors to chemotherapy is not sufficiently clear. Objective. The systematic search and analysis of scientific publications describing studies of the predictive power of expression (high, low) and localization (nuclear, cytoplasmic) of YB-1 for overall survival and progression free survival in patients with breast cancer. Methods. A systematic search was carried out in Medline database and the Cochrane Library in April 2014. Of the 88 studies found, we selected for further analysis 2 prospective cohort studies and 7 retrospective studies. We assessed the methodological quality of the selected studies taking into account study design, the risks of systematic biases and risks of incorrect statistical analysis. Results. The included studies varied in their methodological quality (from IIa to IIIc). The expression level (high vs. low) of YB-1 protein when localized in the nucleus of tumor cells is a predictor of overall survival (OS) in patients with breast cancer. The predictive role of cytoplasm localization of YB-1 for OS is not proven. The role of the protein expression level of YB-1 as a predictor ofprogression free survival (PFS) is not proven both for nucleus and cytoplasm localizations. The role of protein localization of YB-1 (nucleus vs. cytoplasm) at high and low levels of expression as a prognostic factor of OS and PFS in patients with breast cancer requires further studies.
Russian Journal of Oncology. 2015;20(1):4-12
pages 4-12 views

Capecitabine in combination with radiotherapy for treatment of brain metastases in patients with breast cancer

Moskvina E.A., Gorbunova V.A., Naskhletashvili D.R., Medvedev S.V., Bekyashev A.K., Belov D.M.


The article reviews the experience of capecitabine application in 65 breast cancer (BC) patients with metastatic brain damage. 35 patients underwent early chemoradiation, (brain irradiation) simultaneously with the start of capecitabine. In 30 patients delayed chemoradiation was conducted, in the first phase - induction chemotherapy with capecitabine, then brain irradiation in patients receiving capecitabine. The effectiveness of the immediate and long-term outcomes in the two groups was analyzed. In the group of early chemoradiotherapy objective effect in the brain was 77.2%. The median time to progression - 15.3 months. The median survival - 22 months. In the group of delayed chemoradiotherapy objective effect was 56.6%. The median time to progression - 12 months. The median life expectancy - 15.1 month. When comparing the time to disease progression in the brain in early chemoradiotherapy group (15.3 months), and the group of delayed chemoradiotherapy (12 months), and also when comparing the median survival in early groups (22 months) and delayed (15, 1 month.) chemoradiotherapy statistically significant differences were found (p = 0.3; p = 0.25, respectively). The reviewed modes of chemoradiotherapy with capecitabine (early and delayed chemoradiotherapy) had comparable effectiveness.
Russian Journal of Oncology. 2015;20(1):13-17
pages 13-17 views

Heterogeneity of breast cancer I stage: clinical and prognostic value of the carcinoma size T1A, T1B and T1C

Kolyadina I.V., Poddubnaya I.V., Trofimova O.P., Frank G.A., Komov D.V., Karseladze A.I., Ozhereliev A.S.


During last 25 years there has been a progressive increase in the share of «small» tumors (T1a and T1b) in breast cancer stage I. Biological characteristics of tumor size T1a, T1b and T1c are different. Tumors less then 5mm have favorable biology: a high rate of luminal A subtype of breast cancer that affects the minimum proportion of relapses of the breast cancer and high rates of long-term survival. Biological characteristics of tumor with T1b and T1c size are more aggressive and presented by a high frequency of ductal carcinoma with luminal B and triple-negative immunophenotype, which significantly decreases the prognosis of the disease. Biology «small» tumors should be considered for choosing the optimal adjuvant treatment algorithm for breast cancer stage I.
Russian Journal of Oncology. 2015;20(1):17-22
pages 17-22 views

Clinical prospects of insulin-like growth factors and IGF binding proteins study in blood serum of ovarian cancer patients

Isaeva E.R., Gershtein E.S., Kushlinsky D.N., Korotkova E.A., Ermilova V.D., Tereshkina I.V., Laktionov K.P., Adamyan L.V.


IGF-I, II, IGFBP-1, 2 and 3 levels were measured with standard ELISA kits (Mediagnost) in blood serum of 44 ovarian cancer, 12 benign and 11 borderline ovarian tumorpatients. Control group comprised 33 practically healthy women. Serum IGF-1 content in ovarian cancer patients was significantly lower, and IGFBP-1 content - higher than in all other groups. IGFBP-2 level was increased both in ovarian cancer and borderline tumor groups as compared to control and benign ovarian tumor patients. No significant associations were found between the majority ofparameters studied and main clinico-pathologic characteristics of ovarian cancer. Thus, disturbances in IGFs/IGBPs balance were revealed in blood serum of ovarian cancer patients, and IGFBP-2 proved to be a potential diagnostic serological marker with 90% specificity and 90% sensitivity.
Russian Journal of Oncology. 2015;20(1):22-25
pages 22-25 views

Chemoradiotherapy of squamous cell anal cancer

Elizbaryan K.S., Lazarev A.F., Shoykhet Y.N., Davidenko I.S., Kaushanskaya S.Y., Davidenko O.V., Gorcovoi A.V., Bublik M.V., Vasilenko I.N.


Squamous cell carcinoma of the anal canal is a rare disease and is no more than 1.7-2% of the annual cancer incidence. Chemoradiation therapy - the standard modern treatment of squamous cell anal cancer. Short-term recurrence-free period of the new approaches to the treatment of anal cancer, in particular to the new regimes chemoradiotherapy.
Russian Journal of Oncology. 2015;20(1):26-29
pages 26-29 views

Advisability of long-term anticoagulant therapy in oncology

Shilova A.N., Karpenko A.A., Klevanets J.E., Karmadonova N.A.


The article gives a detailed description of the clinical case of acute massive pulmonary embolism in a patient who underwent surgery for cancer of the corpus uteri. Endovascular recanalization of the pulmonary arteries, supplemented with thrombolytic therapy, followed by long-term anticoagulant therapy led to a successful outcome. We confirmed the needfor anticoagulant therapy in the postoperative period in cancer patients, both in early and late periods of follow-up.
Russian Journal of Oncology. 2015;20(1):30-32
pages 30-32 views

Search for new antitumor compounds among n-glycoside indolo[2,3-a]carbazole derivatives

Kiseleva M.P., Smirnova Z.S., Borisova L.M., Kubasova I.Y., Ektova L.V., Miniker T.D., Plikhtiak I.L., Medvedeva L.A., Eremina V.A., Tikhonova N.I.


The study investigated antitumor activity of 10 new compounds in the series of N-glycosides of indolo[2,3-a] carbazoles. The results identified strong antitumor activity of compounds LCS-1208, LCS -1054, LCS -999 and LCS-1006 against lymphocytic leukemia P-388 (ILS=85 - 119%). Glycosides LCS-1208, LCS-999 and LCS-1006 exhibited high antitumor activity immediately after treatment for Lewis epidermoid lung carcinoma LLC (TGI =90%). In addition, the antitumor effect after LCS-999 and LCS-1006 treatment kept on for 10 days, and LCS-1208 - for 15 days. Glycoside LCS-1208 had a therapeutic efficiency on melanoma B-16 for 7 days (TGI=91 - 58%). Thus, the study of relation «structure-activity» in a series of derivatives of N-glycosides of indolo[2,3-a]carbazoles allowed to select highly effective compound LCS-1208 for preclinical studies.
Russian Journal of Oncology. 2015;20(1):33-37
pages 33-37 views

The incidence of malignant neoplasms in the Azerbaijan Republic

Aliyev D.A., Mardanli F.A., Vatankha S.S., Farkhadzadeh K.B.


Statistical analysis showed that the highest incidence of malignant tumors was observed in males at diseases of the trachea, bronchus, lung, intensive index, which was 18,9 % ooo and gastric malignancies (15,3 % ooo). Individuals female lead position taken by the disease, breast cancer and cervical cancer, intense incidence which was 31,8 % ooo and 7,0 % ooo, respectively. The greatest increase in the incidence of malignant tumors observed in both males and in females in the age group 50-59 years, which standardized ratio was 30,8 and 29,4 % ooo respectively. Revealed that the greatest cause of mortality and mortality in men were malignant neoplasms of the stomach (0.2 and 47.9% ooo respectively) and the trachea, bronchus and lung (0.1 and 51.2% ooo respectively), women - malignant neoplasm of breast (0.1 and 14.1% ooo respectively). Aggressiveness factor most likely expressed in malignant tumors of the stomach (1.3) in men and bladder (1.7), trachea, bronchus and lung (0.9) and the lips (0.8) in women.
Russian Journal of Oncology. 2015;20(1):38-41
pages 38-41 views

Breast cancer screening: world experience and prospects

Kolyadina I.V., Poddubnaya I.V., Komov D.V.


Breast cancer screening (breast examination in potentially healthy women for early, preclinical detection of malignancies) was introduced in the 60s last century in the United States, and then in the number of countries in the world. Many years of experience has shown important clinical and prognostic value of mammographic screening programs for increasing the proportion of carcinoma in situ and breast cancer stage I, which led to significant improvement in the long-term survival. The review presents the main stages of the screening programs, differences in the organization of screening in different countries, and also gives the definition of «screening age,» high-risk factors for breast cancer appearing and possible intensification of early detection programs. The existing screening methods have described, their advantages and disadvantages, as well as highlighted possible areas for screening programs.
Russian Journal of Oncology. 2015;20(1):42-46
pages 42-46 views

Analysis of current MRI capabilities in diagnosis of the focal liver lesions

Romanova K.A.


This is an overview of current approaches to liver magnetic resonance imaging (MRI) particularly diffusion-weighted (DW) MRI that supposed to be a promising tool for the detection and characterization offocal liver lesions. Basic principles of DW MR imaging, typical DWI features offocal liver lesions, difficulties in differentiating benign from malignant, monitoring and predicting treatment response are highlighted.
Russian Journal of Oncology. 2015;20(1):47-54
pages 47-54 views

In memory of Klipfel' Artur Evgen'evich

- -.
Russian Journal of Oncology. 2015;20(1):55-55
pages 55-55 views

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies